Crizotinib (Xalkori) for Non-Small Cell Lung Cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2012年 / 54卷 / 1383期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [21] CrizotinibAcquired resistance to crizotinib in non-small lung cancer: case report
    Reactions Weekly, 2017, 1648 (1) : 103 - 103
  • [22] Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients
    Dasom Jung
    Ji Min Han
    Jeong Yee
    Jae Youn Kim
    Hye Sun Gwak
    Medical Oncology, 2018, 35
  • [23] Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement
    Zhang, Chao
    Li, Shao-lei
    Nie, Qiang
    Dong, Song
    Shao, Yang
    Yang, Xue-ning
    Wu, Yi-long
    Yang, Yue
    Zhong, Wen-zhao
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 726 - 731
  • [24] Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients
    Jung, Dasom
    Han, Ji Min
    Yee, Jeong
    Kim, Jae Youn
    Gwak, Hye Sun
    MEDICAL ONCOLOGY, 2018, 35 (12)
  • [25] Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
    Poon, Candice C.
    Kelly, John J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 1945 - 1954
  • [26] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [27] Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer
    Barnes, Tristan A.
    Leighl, Natasha B.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S458 - S461
  • [28] CLINICAL IMPLICATION OF A POPULATION PHARMACOKINETIC ANALYSIS OF XALKORI (CRIZOTINIB) IN 1,182 PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND 32 PATIENTS WITH OTHER SOLID TUMORS
    Wang, Erjian
    Nickens, Dana
    Bello, Akintunde
    Khosravan, Reza
    Amantea, Michael
    Tan, Weiwei
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S296 - S296
  • [29] ROS-1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience
    Talreja, V.
    Patil, V.
    Joshi, A.
    Noronha, V.
    Mv, C.
    Kaushal, R.
    Mahajan, A.
    Janu, A.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2278 - S2278
  • [30] Alectinib/crizotinibAcquired resistance to alectinib and crizotinib in non-small cell lung cancer: case report
    Reactions Weekly, 2018, 1707 (1) : 23 - 23
12345